Arwen Stikvoort

Publikationer
Forskningsbidrag
CV
Populärvetenskap och samverkan

Artiklar

Article: ONCOIMMUNOLOGY. 2024;13(1):2379063
Selective lysis of acute myeloid leukemia cells by CD34/CD3 bispecific antibody through the activation of γδ T-cells
Al Agrafi F; Gaballa A; Hahn P; Arruda LCM; Jaramillo AC; Witsen M; Lehmann S; Onfelt B; Uhlin M; Stikvoort A
Article: JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY. 2023;149(8):4173-4184
Radiation modulates expression and related activities of c-Met protein in oral tongue squamous cell carcinoma cell lines.
Al-Jamaei AAH; de Visscher JGAM; Forouzanfar T; Brakenhoff RH; Leemans CR; Stikvoort A; Zandieh-Doulabi B; Helder MN
Article: HAEMATOLOGICA. 2022;107(8):1786-1795
A novel CD34-specific T-cell engager efficiently depletes acute myeloid leukemia and leukemic stem cells in vitro and in vivo
Arruda LCM; Stikvoort A; Lambert M; Jin L; Rivera LS; Alves RMP; de Moura TR; Mim C; Lehmann S; Axelsson-Robertson R; Dick JE; Mattsson J; Onfelt B; Carlsten M; Uhlin M
Article: HAEMATOLOGICA. 2022;107(2):437-445
CD38 knockout natural killer cells expressing an affinity optimized CD38 chimeric antigen receptor successfully target acute myeloid leukemia with reduced effector cell fratricide.
Gurney M; Stikvoort A; Nolan E; Kirkham-McCarthy L; Khoruzhenko S; Shivakumar R; Zweegman S; Van de Donk NWCJ; Mutis T; Szegezdi E; Sarkar S; O'Dwyer M
Article: HEMASPHERE. 2021;5(7):e596
CD38-specific Chimeric Antigen Receptor Expressing Natural Killer KHYG-1 Cells: A Proof of Concept for an "Off the Shelf" Therapy for Multiple Myeloma
Stikvoort A; van der Schans J; Sarkar S; Poels R; Ruiter R; Naik J; Yuan H; de Bruijn JD; van de Donk NWCJ; Zweegman S; Themeli M; Groen R; O'Dwyer M; Mutis T
Article: HEMASPHERE. 2021;5(5):e561
Bone Marrow Mesenchymal Stromal Cell-mediated Resistance in Multiple Myeloma Against NK Cells can be Overcome by Introduction of CD38-CAR or TRAIL-variant
Holthof LC; Stikvoort A; van der Horst HJ; Gelderloos AT; Poels R; Li F; Groen RWJ; Zweegman S; van de Donk NWCJ; O'Dwyer M; Mutis T
Article: BONE MARROW TRANSPLANTATION. 2019;54(10):1562-1574
T-cell frequencies of CD8⁺ γδ and CD27⁺ γδ cells in the stem cell graft predict the outcome after allogeneic hematopoietic cell transplantation
Gaballa A; Stikvoort A; Onfelt B; Mattsson J; Sundin M; Watz E; Uhlin M
Article: ONCOIMMUNOLOGY. 2019;8(2):e1535730
Immune profiling and identification of prognostic immune-related risk factors in human ovarian cancer
Radestad E; Klynning C; Stikvoort A; Mogensen O; Nava S; Magalhaes I; Uhlin M
Article: TRANSPLANTATION AND CELLULAR THERAPY. 2018;24(3):467-477
Risk Factors for Severe Acute Graft-versus-Host Disease in Donor Graft Composition
Stikvoort A; Gaballa A; Solders M; Nederlof I; Onfelt B; Sundberg B; Remberger M; Sundin M; Mattsson J; Uhlin M
Article: JOURNAL OF LEUKOCYTE BIOLOGY. 2017;101(3):623-632
Frontline Science: Placenta-derived decidual stromal cells alter IL-2R expression and signaling in alloantigen-activated T cells
Erkers T; Solders M; Verleng L; Bergstroem C; Stikvoort A; Rane L; Nava S; Ringden O; Kaipe H
Article: FRONTIERS IN IMMUNOLOGY. 2017;8:717
Combining Flow and Mass Cytometry in the Search for Biomarkers in Chronic Graft-versus-Host Disease
Stikvoort A; Chen Y; Radestad E; Torlen J; Lakshmikanth T; Bjorklund A; Mikes J; Achour A; Gertow J; Sundberg B; Remberger M; Sundin M; Mattsson J; Brodin P; Uhlin M
Article: PLOS ONE. 2016;11(5):e0154737
Long-Term Stable Mixed Chimerism after Hematopoietic Stem Cell Transplantation in Patients with Non-Malignant Disease, Shall We Be Tolerant?
Stikvoort A; Sundin M; Uzunel M; Gertow J; Sundberg B; Schaffer M; Mattsson J; Uhlin M
Article: JOURNAL OF IMMUNOLOGY RESEARCH. 2016;2016:5601204-11
Donor Cell Composition and Reactivity Predict Risk of Acute Graft-versus-Host Disease after Allogeneic Hematopoietic Stem Cell Transplantation
Sairafi D; Stikvoort A; Gertow J; Mattsson J; Uhlin M
Article: PROSTATE. 2014;74(14):1391-1399
Novel Method to Characterize Immune Cells From Human Prostate Tissue
Norstrom MM; Radestad E; Stikvoort A; Egevad L; Bergqvist M; Henningsohn L; Mattsson J; Levitsky V; Uhlin M
Article: TRANSPLANTATION AND CELLULAR THERAPY. 2013;19(5):838-844
Chimerism Patterns of Long-Term Stable Mixed Chimeras Posthematopoietic Stem Cell Transplantation in Patients with Nonmalignant Diseases: Follow-Up of Long-Term Stable Mixed Chimerism Patients
Stikvoort A; Gertow J; Sundin M; Remberger M; Mattsson J; Uhlin M
Journal article: JOURNAL OF BLOOD DISORDERS & TRANSFUSION. 2012;01(S1)
Mixed Chimerism after Allogeneic Stem Cell Transplantation – Focus on Double Cord Blood Transplantation
Jens G; Arwen S; Emma W; Jonas M

Alla övriga publikationer

Conference publication: BONE MARROW TRANSPLANTATION. 2023;58(SUPP1):355
GAMMA DELTA T CELLS RECONSTITUTION IN LONG-TERM SURVIVORS AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION
Alagrafi F; Stikvoort A; Gaballa A; Arruda L; Poiret T; Uhlin M
Conference publication: BLOOD. 2022;140:8350
Comprehensive Exploration of NK Cell Education in ADCC Triggered By a Monoclonal Antibody or a Bispecific Killer Engager Molecule (BiKE)
Leijonhufvud C; Schlums H; Stikvoort A; Uhlin M; Bryceson YT; Carlsten M
Review: VIRUSES. 2021;13(6):1031
Revisiting the Role of γδ T Cells in Anti-CMV Immune Response after Transplantation
Gaballa A; Alagrafi F; Uhlin M; Stikvoort A
Meeting abstract: BLOOD. 2019;134:5536
Targeting CD38^high Acute Myeloid Leukaemia with "Affinity Optimized" Chimeric Antigen Receptor and Membrane Bound TRAIL Expressing Natural Killer Cells
Nolan E; Stikvoort A; Gurney M; Burduli N; Kirkham-McCarthy L; Daly J; Van de Donk NWCJ; Mutis T; Sarkar S; O'Dwyer ME
Meeting abstract: BLOOD. 2018;132:3199
CD38^low Natural Killer Cells Transiently Expressing CD16^F158V m-RNA Potentiates the Therapeutic Activity of Daratumumab Against Multiple Myeloma with Minimal Effector NK Cell Fratricide
Sarkar S; Chauhan S; Stikvoort A; Natoni A; Daly J; Henderson R; Mutis T; O'Dwyer ME
Meeting abstract: BLOOD. 2018;132:3261
CD38 Specific Chimeric Antigen Receptor KHYG-1 Natural Killer Cells: A Potential "Off the Shelf" Therapy for Multiple Myeloma
Stikvoort A; Sarkar S; Poels R; van de Donk NWCJ; Zweegman S; O'Dwyer ME; Mutis T
Published conference paper: BONE MARROW TRANSPLANTATION. 2018;53(1):69-77
Assessment of TREC, KREC and telomere length in long-term survivors after allogeneic HSCT: the role of GvHD and graft source and evidence for telomere homeostasis in young recipients
Gaballa A; Norberg A; Stikvoort A; Mattsson J; Sundberg B; Uzunel M; Remberger M; Uhlin M
Review: STEM CELLS INTERNATIONAL. 2017;2017:5738371-17
Lymphocytes in Placental Tissues: Immune Regulation and Translational Possibilities for Immunotherapy
Erkers T; Stikvoort A; Uhlin M
Conference publication: SCANDINAVIAN JOURNAL OF IMMUNOLOGY. 2017;86(4):264
Identifying cellular subsets diagnostic for severity chronic GVHD
Stikvoort A; Chen Y; Radestad E; Karlsson-Torlen J; Tadepally L; Bjorklund A; Mikes J; Achour A; Gertow J; Sundberg B; Remberger M; Sundin M; Mattsson J; Brodin P; Uhlin M
Conference publication: SCANDINAVIAN JOURNAL OF IMMUNOLOGY. 2017;86(4):265
Assessment of TREC, KREC and telomere length in long term survivors after allogeneic HSCT: the role of GVHD and graft source and evidence for telomere homeostasis in young recipients
Gaballa A; Norberg A; Stikvoort A; Mattsson J; Sundberg B; Uzunel M; Remberger M; Uhlin M
Review: INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES. 2016;17(10):E1705-1705
T Cell Receptor Excision Circle (TREC) Monitoring after Allogeneic Stem Cell Transplantation; a Predictive Marker for Complications and Clinical Outcome
Gaballa A; Sundin M; Stikvoort A; Abumaree M; Uzunel M; Sairafi D; Uhlin M
Meeting abstract: TRANSPLANTATION AND CELLULAR THERAPY. 2016;22(3):S415
Identifying Cellular Subsets Diagnostic for Severity and Organ Specific Chronic GVHD
Stikvoort A; Rodestad E; Gertow J; Torlen J; Sundin M; Mattsson J; Uhlin M
Meeting abstract: TRANSPLANTATION AND CELLULAR THERAPY. 2016;22(3):S179-S180
Prophylaxis for Herpes Simplex Virus Reactivation in Patients after Allogeneic Hematopoietic Stem Cell Transplantation; Effects and Clinical Outcome
Uhlin M; Stikvoort A; Sundin M; Mattsson J; Remberger M
Conference publication: EUROPEAN JOURNAL OF IMMUNOLOGY. 2016;46:845
Placenta-derived decidual stromal cells alter IL-2R expression and signaling in alloantigen-activated T cells
Erkers T; Solders M; Verlang L; Bergstrom C; Stikvoort A; Rane L; Nava S; Ringden O; Kaipe H
Conference publication: EUROPEAN JOURNAL OF IMMUNOLOGY. 2016;46:844
Identifying cellular subsets diagnostic for severity and organ specificity chronic GVHD
Stikvoort A; Chen Y; Radestad E; Torlen J; Sundberg B; Sundin M; Mattsson J; Brodin P; Uhlin M
Meeting abstract: TRANSPLANTATION AND CELLULAR THERAPY. 2015;21(2):S170
Risk Factors and Clinical Outcome for Herpes Simplex Virus Reactivation in Patients after Allogeneic Hematopoietic Stem Cell Transplantation
Uhlin M; Stikvoort A; Sundin M; Mattsson J; Remberger M
Meeting abstract: TRANSPLANTATION AND CELLULAR THERAPY. 2015;21(2):S351
An Increasing Severity of Chronic GvHD Is Associated to an Activated and Cytotoxic T Cell Mediated Immune-Phenotype
Stikvoort A; Radestad E; Torlen J; Mattsson J; Uhlin M
Meeting abstract: TRANSPLANTATION AND CELLULAR THERAPY. 2015;21(2):S182-S183
Long-Term Stable Mixed Chimerism in Patients Undergoing HSCT for Non-Malignant Disorders
Stikvoort A; Mattsson J; Sundin M; Uhlin M
Conference publication: BONE MARROW TRANSPLANTATION. 2015;50:S407-S408
Risk factors and clinical outcome for Herpes Simplex Virus reactivation in patients after allogeneic hematopoietic stem cell transplantation
Uhlin M; Stikvoort A; Sundin M; Mattsson J; Remberger M
Conference publication: BONE MARROW TRANSPLANTATION. 2015;50:S236
Long-term stable mixed chimerism in patients undergoing HSCT for non-malignant disorders
Stikvoort A; Mattsson J; Sundin M; Uhlin M; Sundberg B; Uzunel M
Conference publication: HLA. 2014;84(1):32
AN INCREASING SEVERITY OF cGvHD IS ASSOCIATED TO A MORE ACTIVATED AND CYTOTOXIC T-CELL MEDIATED IMMUNE-PHENOTYPE
Stikvoort A; Radestad E; Gertow J; Sundin M; Mattsson J; Uhlin M
Conference publication: BONE MARROW TRANSPLANTATION. 2014;49:S536-S537
AN INCREASING SEVERITY OF CGVHD IS ASSOCIATED TO A MORE ACTIVATED AND CYTOTOXIC T-CELL MEDIATED IMMUNE-PHENOTYPE
Stikvoort A; Radestad E; Gertow J; Sundin M; Mattsson J; Uhlin M
Conference publication: BONE MARROW TRANSPLANTATION. 2013;48:S248
Chimerism patterns of long-term stable mixed chimeras post-HSCT in patients with non-malignant diseases
Stikvoort A; Gertow J; Sundin M; Remberger M; Mattsson J; Uhlin M
Visa fler

Forskningsbidrag

Felix Mindus bidrag till leukemiforskningen
1 January 2024 - 31 December 2024
CIMED
1 January 2023 - 31 December 2025
Dr Åke Olssons stiftelse
1 January 2022 - 31 December 2022

Anställningar

Biträdande Lektor, Medicin, Huddinge, Karolinska Institutet, 2024-2026
Biträdande Lektor, Klinisk vetenskap, intervention och teknik, Karolinska Institutet, 2022-2024
Postdoktor, Klinisk vetenskap, intervention och teknik, Karolinska Institutet, 2020-2022
Postdoctoral researcher, Hematology, Amsterdam UMC, 2018-2020

Examina och utbildning

Medicine Doktorsexamen, Institutionen för onkologi-patologi, Karolinska Institutet, 2017

Artiklar

Alla övriga publikationer

Forskningsbidrag

Anställningar

Examina och utbildning

Nyheter från KI

Kalenderhändelser från KI